NOTICES
STATE HORSE RACING COMMISSION
Schedule of Therapeutic Substances
[43 Pa.B. 7612]
[Saturday, December 28, 2013]The State Horse Racing Commission (Commission), in accordance with the Race Horse Industry Reform Act (4 P. S. §§ 325.101—325.402), and more specifically 58 Pa. Code § 163.304 (relating to substances of therapeutic value), adopts the schedule of therapeutic medications established by the Racing Medication and Testing Consortium (RMTC) and adopted by the Association of Racing Commissioners International (ARCI).
Under 58 Pa. Code § 163.304, the Commission may approve and adopt by reference the RMTC/ARCI schedule of therapeutic medications and their respective threshold levels. On July 11, 2013, at its public meeting the Commission formally approved the schedule set forth as follows. This schedule shall take effect on January 1, 2014. The Commission will publish any subsequent amendments or additions to the RMTC/ARCI therapeutic schedule.
The Commission did not engage in an independent testing evaluation of the administration times or administration dosage for these medications. Individuals using the enumerated therapeutic medications are encouraged to seek the advice of their respective Veterinarians.
RMTC
Controlled Therapeutic Medications
Substance Restricted
Administration TimeThreshold Route of Administration Experimental Administration Dosage Acepromazine 48 hours HEPS—10 ng/mL of urine Intravenous 0.05 mg/kg Betamethasone 7 days 10 pg/mL in plasma or
serumslntra-articular 9 mg total in one articular space Butorphanol 48 hours Free butorphanol—
2 ng/mL of plasma, or
Total butorphanol—
300 ng/mL of urine.Intravenous 0.1 mg/kg Clenbuterol 14 days 140 pg/mL of urine or
LOD in plasmaOral 0.8 mcg/kg Dantrolene 48 hours 5-OH dantrolene—
0.1 ng/mL of plasma
or serumOral 500 mg total dose Detomidine 72 hours 1 ng/mL of carboxy-
detomidine in
urine; LOD for detomidine
in plasmaSublingual detomidine (Domosedan gel) 40 mcg/kg Dexamethasone 72 hours 5 pg/mL of plasma or
serumOral, Intravenous,
IM0.05 mg/kg Diclofenac 48 hours 5 ng/mL of plasma or
serumTopical 5" ribbon of Surpass every 12 hours to one site DMSO 48 hours 10 mcg/mL of plasma or serum Oral or IV Firocoxib 14 days 20 ng/nriL of plasma or serum Oral 0.1 mg/kg for 4 days Flunixin 24 hours 20 ng/mL of plasma or
serumIntravenous 1.1 mg/kg Furosemide 4 hours 100 ng/mL in blood and
urine specific gravity
< 1.010Intravenous Up to 500 mg total dose Glycopyrrolate 48 hours 3 pg/mL of plasma or
serumIntravenous 1 mg total dose Ketoprofen 24 hours 10 ng/mL of plasma or
serumIntravenous 2.2 mg/kg Lidocaine (interim) 72 hours 20 pg/mL of total 30H-lidocaine in plasma Subcutaneous—
distal limb200 mg of lidocaine Hydrochloride salt Mepivacaine 72 hours 30H-mepivacaine—10 ng/mL in urine or mepivacaine at LOD in plasma Subcutaneous—
distal limb0.07 mg/kg Methocarbamol 48 hours 1 ng/mL of plasma or
serumIV or Oral 15 mg/kg IV, 5 g oral Methylprednisolone 7 days 100 pg/mL in plasma or serum Intra-articular 100 mg total in one articular space * Omeprazole 24 hours omeprazole sulfide—
1 ng/mL in urineOral 3.9 mg/kg Phenylbutazone 24 hours 2 mcg/mL of plasma or
serumIntravenous 4 mg/kg Prednisolone 48 hours 1 ng/mL of plasma or serum Oral 1 mg/kg Procaine penicillin Time of entry 25 ng/mL of plasma Intra-muscular Triamcinolone acetonide 7 days 100 pg/mL of plasma or serum Intra-muscular 9mg total in one articular space Xylazine (interim) 48 hours 0.01 ng/mL of plasma Intravenous * Note: At the 100 mg experimental dose, the safe time for administration to meet the 100 pg/mL threshold was 21 days—the 7 day withdrawal time anticipates that protocols vary and a smaller dose may be utilized which may allow plasma concentrations to fall below the threshold more quickly.
WALTER REMMERT,
Acting Executive Secretary
[Pa.B. Doc. No. 13-2463. Filed for public inspection December 27, 2013, 9:00 a.m.]
No part of the information on this site may be reproduced for profit or sold for profit.This material has been drawn directly from the official Pennsylvania Bulletin full text database. Due to the limitations of HTML or differences in display capabilities of different browsers, this version may differ slightly from the official printed version.